🇺🇸 FDA

Intelligence · Patent portfolio

Takeda Patents

Full USPTO pharma patent portfolio for Takeda — grant dates, expiration, and drug cross-links.

Patents
1,436
Expiring ≤24m
81

Quick answer

Takeda has 1,436 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 81 expire within 24 months — use filters for patent-cliff planning.

Page 12 of 30

  1. US 9433632

    Dry coated tablet

    Expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9434743

    Indazole derivatives

    Expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9428470

    Heterocyclic compound

    Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9427434

    Coated preparation

    Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9422327

    Process for preparing crystalline ciclesonide with defined particle size

    Expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9403819

    Apoptosis signal-regulating kinase 1 inhibitors

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9402841

    Pyridinyl and fused pyridinyl triazolone derivatives

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9403802

    Heterocyclic compound and use therefor

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9388195

    Heterocyclic compound

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9387205

    Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9387249

    Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9382188

    Aromatic ring compound

    Expires Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9376442

    Methylpyrrolopyrimidinecarboxamides

    Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9371320

    Heterocyclic compound

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9365540

    Benzimidazole derivatives as MCH receptor antagonists

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9364438

    Process for producing solid particles

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9365520

    Heterocyclic compound

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9365566

    Cinnoline derivatives

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9359410

    Virus like particle purification

    Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9353108

    Tetrahydronaphthyridine somatostatin receptor 5 antagonists

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9346829

    5-HT3 receptor antagonists

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9345713

    6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9346783

    Method and apparatus for producing oxidized compound

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9346822

    Thienopyrimidine compounds and use thereof

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9346776

    Fused heterocyclic compound

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9340522

    Pyrazolone-derivatives and their use as PDE-4 inhibitors

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9326946

    Laminated tablet and manufacturing method therefor

    Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9321757

    Heterocyclic compound

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9320714

    Tablet

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9315458

    Nitrogen-containing heterocyclic compound

    Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9309187

    EP2 receptor agonists

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9308249

    Norovirus vaccine formulations

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9303045

    5-HT3 receptor antagonists

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9296746

    Heterocyclic compound

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9290456

    Pyridazinone compounds and their use as DAAO inhibitors

    Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9278938

    Production method of imidazole derivatives

    Expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9278096

    Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity

    Expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9278931

    Cyclopropaneamine compound

    Expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9272028

    Norovirus vaccine formulations

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9265730

    Stable solid preparations

    Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9260500

    Peptide and use thereof

    Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9255063

    Colchicine solid-state forms; methods of making; and methods of use thereof

    Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9248119

    Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors

    Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9241910

    Orally-disintegrating solid preparation

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9238029

    Multiple PPI dosage form

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9238639

    Aromatic ring compound

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9233103

    Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9226921

    Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors

    Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Takeda have?

1,436 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Takeda patents expire?

81 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.